Eradication of H. Pylori Infection With Moxifloxacin

• Status: Completed
• Trial end date: 2022-06-08
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of the study is to compare the effectiveness of moxifloxacin triple therapy with levofloxacin-based sequential therapy in terms of eradication rate, safety, and patient compliance.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Iyad Naeem Muhammad, PhD
• Treatments: Amoxicillin; Levofloxacin; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination; Ofloxacin; Omeprazole; Tinidazole

Criteria

Inclusion Criteria:

1. Successful isolation of H. pylori from the patient, and

2. patients of at least 18 years of age.

Exclusion Criteria:

1. age under 18 years

2. presence of clinically significant associated conditions (insulin-dependent diabetes mellitus, gastrointestinal bleeding, neoplastic diseases, coagulation disorders, and neurologic, metabolic, hematological or endocrine hepatic, cardiorespiratory, or renal diseases),

3. previous gastric surgery,

4. allergy to any of the drugs used in the study, and (5) pregnancy or breastfeeding.